cutaneous administration

Summary

Summary: The application of suitable drug dosage forms to the skin for either local or systemic effects.

Top Publications

  1. pmc Transdermal drug delivery
    Mark R Prausnitz
    School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, 311 Ferst Dr, Atlanta, Georgia 30332 0100, USA
    Nat Biotechnol 26:1261-8. 2008
  2. ncbi Transdermal delivery of insulin using microneedles in vivo
    Wijaya Martanto
    School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
    Pharm Res 21:947-52. 2004
  3. ncbi Dermal and transdermal drug delivery systems: current and future prospects
    Marc B Brown
    Pharmaceutical Sciences Research Division, King s College London and MedPharm Ltd, London, United Kingdom
    Drug Deliv 13:175-87. 2006
  4. ncbi Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial
    Werner H Poewe
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Lancet Neurol 6:513-20. 2007
  5. ncbi Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole
    Nir Giladi
    Movement Disorders Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Mov Disord 22:2398-404. 2007
  6. ncbi Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease
    Rafael Blesa
    Hospital de la Sta Creu i Sant Pau, Barcelona, Spain
    Neurology 69:S23-8. 2007
  7. ncbi Nanoparticles--an efficient carrier for drug delivery into the hair follicles
    Juergen Lademann
    Charite Universitatsmedizin Berlin, Department of Dermatology, Berlin, Germany
    Eur J Pharm Biopharm 66:159-64. 2007
  8. ncbi Penetration of metallic nanoparticles in human full-thickness skin
    Biancamaria Baroli
    Dipartimento Farmaco Chimico Tecnologico, Facolta di Farmacia, Universita di Cagliari, Cagliari, Italy
    J Invest Dermatol 127:1701-12. 2007
  9. ncbi 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin
    Annika Vogt
    Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Physiology, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Invest Dermatol 126:1316-22. 2006
  10. ncbi A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule
    Bengt Winblad
    Karolinska Institutet Alzheimer Research Center, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:456-67. 2007

Research Grants

  1. Therapeutic vaccination against genital HPV infection
    Yung Nien Chang; Fiscal Year: 2013
  2. Mucosal Immune-enhancing Delivery System for HIV vaccines
    MICHAEL SEJR VAJDY; Fiscal Year: 2010
  3. Comparative In Vivo Biodistribution of Characterized Manufactured Nanomaterials
    Nancy A Monteiro Riviere; Fiscal Year: 2010
  4. Novel therapeutics for learning and memory disorders
    Joseph Moskal; Fiscal Year: 2006
  5. Non-viral Cutaneous Gene Delivery
    Mohammed Kashani Sabet; Fiscal Year: 2005
  6. A NEW METHOD FOR TREATING SLEEP DISORDERS
    Larry Nichols; Fiscal Year: 2000
  7. TOPICAL APPLICATION OF STATINS FOR OSTEOPOROSIS
    I Garrett; Fiscal Year: 2000
  8. VACCINATION BY TOPICAL APPLICATION OF CONDENSED DNA
    Mark Cooper; Fiscal Year: 2000
  9. A Transdermal Hypolipidemic Niacin Prodrug
    Hyuntae Kim; Fiscal Year: 2002
  10. Neurocognition, Nicotine and Polysubstance Abuse
    Sara Nixon; Fiscal Year: 2006

Detail Information

Publications234 found, 100 shown here

  1. pmc Transdermal drug delivery
    Mark R Prausnitz
    School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, 311 Ferst Dr, Atlanta, Georgia 30332 0100, USA
    Nat Biotechnol 26:1261-8. 2008
    ..Using these novel second- and third-generation enhancement strategies, transdermal delivery is poised to significantly increase its impact on medicine...
  2. ncbi Transdermal delivery of insulin using microneedles in vivo
    Wijaya Martanto
    School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
    Pharm Res 21:947-52. 2004
    ..The purpose of this study was to design and fabricate arrays of solid microneedles and insert them into the skin of diabetic hairless rats for transdermal delivery of insulin to lower blood glucose level...
  3. ncbi Dermal and transdermal drug delivery systems: current and future prospects
    Marc B Brown
    Pharmaceutical Sciences Research Division, King s College London and MedPharm Ltd, London, United Kingdom
    Drug Deliv 13:175-87. 2006
    ..This article provides a detailed review of the next generation of active delivery technologies...
  4. ncbi Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial
    Werner H Poewe
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Lancet Neurol 6:513-20. 2007
    ....
  5. ncbi Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole
    Nir Giladi
    Movement Disorders Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Mov Disord 22:2398-404. 2007
    ..Application-site reactions were predominantly mild or moderate in intensity. In conclusion, the rotigotine transdermal patch represents an effective and safe option for the treatment of patients with early Parkinson's disease...
  6. ncbi Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease
    Rafael Blesa
    Hospital de la Sta Creu i Sant Pau, Barcelona, Spain
    Neurology 69:S23-8. 2007
    ..Preference for the patch may indicate reduced caregiver stress, substantiated by greater satisfaction and less interference with daily life. These benefits may lead to improved compliance...
  7. ncbi Nanoparticles--an efficient carrier for drug delivery into the hair follicles
    Juergen Lademann
    Charite Universitatsmedizin Berlin, Department of Dermatology, Berlin, Germany
    Eur J Pharm Biopharm 66:159-64. 2007
    ..Taking into consideration the surface structure of the hair follicles, it was assumed that the movement of the hairs may act as a pumping mechanism pushing the nanoparticles deep into the hair follicles...
  8. ncbi Penetration of metallic nanoparticles in human full-thickness skin
    Biancamaria Baroli
    Dipartimento Farmaco Chimico Tecnologico, Facolta di Farmacia, Universita di Cagliari, Cagliari, Italy
    J Invest Dermatol 127:1701-12. 2007
    ..These results represent a breakthrough in skin penetration because it is early evidence where rigid nanoparticles have been shown to passively reach the viable epidermis through the SC lipidic matrix...
  9. ncbi 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin
    Annika Vogt
    Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Physiology, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Invest Dermatol 126:1316-22. 2006
    ..We conclude that 40 nm nanoparticles, but not 750 or 1,500 nm nanoparticles, may be efficiently used to transcutaneously deliver vaccine compounds via the hair follicle into cutaneous APCs...
  10. ncbi A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule
    Bengt Winblad
    Karolinska Institutet Alzheimer Research Center, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:456-67. 2007
    ..To compare the efficacy, safety and tolerability of a novel rivastigmine transdermal patch with conventional rivastigmine capsules and placebo in patients with Alzheimer's disease (AD)...
  11. ncbi Niosomes as carriers for tretinoin. III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin
    Maria Manconi
    Dipartimento Farmaco Chimico Tecnologico, Universita degli Studi di Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
    Int J Pharm 311:11-9. 2006
    ..Moreover, interactions between skin and vesicles seem to depend on physico-chemical properties of the main component of the vesicular bilayer...
  12. ncbi Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery
    N Kanikkannan
    College of Pharmacy, Florida A and M University, Tallahassee, FL 32307, USA
    Curr Med Chem 7:593-608. 2000
    ..Our review also discusses the various factors to be considered in the selection of an appropriate penetration enhancer for the development of transdermal delivery systems...
  13. ncbi Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain
    Craig A Kornick
    Department of Neurology, Memorial Sloan Kettering Cancer Center, Pain and Palliative Care Service, New York, New York, USA
    Drug Saf 26:951-73. 2003
    ..Patients may resume such activities once the absence of these potential adverse effects is documented...
  14. ncbi Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod
    Gerd Rechtsteiner
    Institute for Immunology, Johannes Gutenberg University, Mainz, Germany
    J Immunol 174:2476-80. 2005
    ..Our results obtained by simple e.c. application of an ointment, without further skin irritating procedures, provide the basis for the development of new, easy to use vaccines against cancer or virus-associated diseases...
  15. ncbi Influence of microemulsions on cutaneous drug delivery
    Mads Kreilgaard
    Department of Neurochemistry and Discovery ADME, H Lundbeck A S, Ottiliavej 9, DK 2500, Valby, Denmark
    Adv Drug Deliv Rev 54:S77-98. 2002
    ..However, a few studies have indicated that the internal structure of microemulsions should allow free diffusion of the drug to optimise cutaneous delivery from these vehicles...
  16. ncbi Vulvar lichen sclerosus : pathophysiology and treatment
    Yolanda R Smith
    Department of Obstetrics and Gynecology, The University of Michigan Hospitals Health Systems, Ann Arbor, Michigan 48109 0276, USA
    Am J Clin Dermatol 5:105-25. 2004
    ..In addition, problems specific to children with lichen sclerosus are reviewed...
  17. ncbi Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control
    R B Muijsers
    Adis International Limited, Auckland, New Zealand
    Drugs 61:2289-307. 2001
    ..Adverse reactions related to skin and appendages (i.e. rash and application site reactions - erythema, papules, itching and oedema) were reported in 153 patients with cancer at a frequency between 1 and 3%...
  18. pmc Transdermal influenza immunization with vaccine-coated microneedle arrays
    Dimitrios G Koutsonanos
    Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America
    PLoS ONE 4:e4773. 2009
    ....
  19. ncbi In vivo assessment of safety of microneedle arrays in human skin
    Suzanne M Bal
    Department of Drug Delivery Technology, Leiden Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands
    Eur J Pharm Sci 35:193-202. 2008
    ..This opens the opportunity for dermal and transdermal delivery of drugs and vaccines...
  20. ncbi Current developments using emerging transdermal technologies in physical enhancement methods
    A Nanda
    Faculty of Pharm Sci, M D University, Rohtak, Haryana 124001, India
    Curr Drug Deliv 3:233-42. 2006
    ..This review outlines recent commercial developments in physical transdermal drug delivery technology and the specific devices and applications being targeted by the pharmaceutical industry...
  21. ncbi Particle-based vaccines for transcutaneous vaccination
    Behazine Combadiere
    Institut National de la Santé et de la Recherche Médicale INSERM U543, Universite Pierre et Marie Curie PARIS6, 91 Boulevard de l Hopital, 75634 Paris, France
    Comp Immunol Microbiol Infect Dis 31:293-315. 2008
    ..In this review, we will focus on the use of micro- and nano-particles to target the skin antigen-presenting cells and will discuss recent advances in the field of transcutaneous vaccination in animal models and humans...
  22. ncbi [Percutaneous or intradermal BCG vaccine?]
    Lucia F Bricks
    Dep de Pediatria da FMUSP, and Instituto da Criança do Hospital das Clínicas da Fac de Medicina da Univ da São Paulo, Sao Paulo, SP
    J Pediatr (Rio J) 80:93-8. 2004
    ..To compare the intradermal and percutaneous routes of BCG administration...
  23. ncbi The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial
    Peter K Sand
    Evanston Continence Center, Evanston Northwestern Healthcare, Northwestern University, Feinberg School of Medicine Evanston, IL 60201, USA
    Am J Obstet Gynecol 195:1730-5. 2006
    ..The objective of the study was to determine the impact of overactive bladder on sexual function from a preliminary analysis of the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin study...
  24. ncbi Transdermal hormone therapy: gels and patches
    G Samsioe
    Department of Obstetrics and Gynecology, Lund University Hospital, 221 85 Lund, Sweden
    Climacteric 7:347-56. 2004
    ..Patch and gel formulations are equally as effective in treating climacteric symptoms and improving bone mineral density, and the effects are comparable to those achieved by oral HT...
  25. ncbi Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl
    Andrew T Goldstein
    Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    J Pediatr Adolesc Gynecol 17:35-7. 2004
    ..As lichen sclerosus is a T-lymphocyte mediated disorder, it has been suggested that pimecrolimus, a topical T-lymphocyte inhibitor, may be safe and effective for the treatment of lichen sclerosus in children...
  26. ncbi Comparison of transdermal administration of fentanyl versus intramuscular administration of butorphanol for analgesia after onychectomy in cats
    Kelly L Gellasch
    Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison 53706, USA
    J Am Vet Med Assoc 220:1020-4. 2002
    ..m. injection of butorphanol...
  27. ncbi Transdermal buprenorphine in the treatment of chronic pain
    Reinhard Sittl
    University of Erlangen, Pain Clinic, Krankenhausstr, 91054 Erlangen, Germany
    Expert Rev Neurother 5:315-23. 2005
    ..Most adverse events were either local reactions to the patch that generally subsided within 24 h or systemic events typical of treatment with opioid analgesics, such as nausea, vomiting and constipation...
  28. pmc Sociodemographic predictors of success in smoking intervention
    E Monso
    Servei de Pneumologia, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
    Tob Control 10:165-9. 2001
    ..To examine the role of sociodemographic factors as predictors of sustained smoking cessation for the population who volunteer to participate in intervention programmes...
  29. ncbi Frequency and thermal effects on the enhancement of transdermal transport by sonophoresis
    Gustavo Merino
    School of Pharmacy, University of Geneva, 30 quai E Ansermet, CH 1211 4, Geneva, Switzerland
    J Control Release 88:85-94. 2003
    ..Only 25% of this enhancement was attributable to the increased temperature induced by US. It follows that another mechanism, most probably cavitation, is principally responsible for the lowered skin barrier function observed...
  30. ncbi Effect of sonication parameters on transdermal delivery of insulin to hairless rats
    Alain Boucaud
    GIP Ultrasons, Faculty of Medicine, 2 bis Boulevard Tonnelle, BP 3223, 37032 Cedex, Tours, France
    J Control Release 81:113-9. 2002
    ..Sonophoresis may therefore potentially be applied for non-invasive and painless delivery of insulin in the treatment of insulin-dependent diabetes...
  31. ncbi New horizons--alternative routes for insulin therapy
    David R Owens
    Diabetes Research Unit, Llandough Hospital, University of Wales College of Medicine, Cardiff, Wales CF64 2XX, UK
    Nat Rev Drug Discov 1:529-40. 2002
    ..Maximizing glucose control in diabetic patients requires several daily injections. In an effort to reduce this burden, alternative and less-intrusive routes for the administration of insulin are being explored...
  32. ncbi Theoretical description of transdermal transport of hydrophilic permeants: application to low-frequency sonophoresis
    H Tang
    Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
    J Pharm Sci 90:545-68. 2001
    ..The observed different roles of convection during LFS across HSS and FTS can be attributed to the different degrees of structural alteration that these two types of skin undergo during LFS...
  33. ncbi Iontophoretic drug delivery
    Yogeshvar N Kalia
    School of Pharmacy, University of Geneva, Geneva, Switzerland
    Adv Drug Deliv Rev 56:619-58. 2004
    ..In the final section, we describe the development of the first pre-filled, pre-programmed iontophoretic device, which is scheduled to be commercialized during the course of 2004...
  34. ncbi Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate
    Carlo Campagnoli
    Unit of Endocrinological Gynaecology, Azienda Ospedaliera O I R M Sant Anna, c so Spezia, 60 10127 Torino, Italy
    Maturitas 41:299-311. 2002
    ....
  35. pmc Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge
    Qiyun Zhu
    Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA
    Proc Natl Acad Sci U S A 106:7968-73. 2009
    ..These results show that MNs are highly effective as a simple method of vaccine delivery to elicit protective immune responses against virus infection...
  36. ncbi Microfabrication of individual 200 microm diameter transdermal microconduits using high voltage pulsing in salicylic acid and benzoic acid
    L Ilic
    Harvard-MIT Health Science and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    J Invest Dermatol 116:40-9. 2001
    ..01 atm (about 10(2) Pa). This study provides a method for rapidly microengineering a pathway in the skin to interface future devices for transdermal drug delivery and sampling of biologically relevant fluids...
  37. ncbi Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users
    J Alexander Cole
    i3 Drug Safety, Auburndale, Massachusetts, USA
    Obstet Gynecol 109:339-46. 2007
    ....
  38. ncbi Quantitative assessment of the transport of elastic and rigid vesicle components and a model drug from these vesicle formulations into human skin in vivo
    P Loan Honeywell-Nguyen
    Department of Pharmaceutical Technology, Leiden Amsterdam Center for Drug Research, University of Leiden, Leiden, The Netherlands
    J Invest Dermatol 123:902-10. 2004
    ..The elastic vesicles are superior to the rigid vesicles both in terms of vesicular transport into the SC and in terms of therapeutic potential as a skin delivery vehicle...
  39. ncbi Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system
    Georg Widera
    ALZA Corporation, Physiological Systems, 1900 Charleston Road, Mountain View, CA 94039 7210, USA
    Vaccine 24:1653-64. 2006
    ..Overall, the microneedle array proves to be a very versatile delivery technology, allowing easy and reproducible antigen delivery to skin for efficient vaccination without the use of a needle and syringe...
  40. ncbi Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain
    Laurie Allan
    Northwick Park and St Marks NHS Trust, Harrow, Middlesex, UK
    Spine (Phila Pa 1976) 30:2484-90. 2005
    ..Open, randomized, parallel group multicenter study...
  41. ncbi Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease
    Werner M Güldenpfennig
    Little Company of Mary Medical Centre, Pretoria, South Africa
    Clin Neuropharmacol 28:106-10. 2005
    ..These data suggest that rotigotine is a safe, well-tolerated, and effective treatment for early-stage Parkinson disease...
  42. ncbi Effect of lipid bilayer alteration on transdermal delivery of a high-molecular-weight and lipophilic drug: studies with paclitaxel
    Ramesh Panchagnula
    Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research NIPER, Sector 67, Phase X, Mohali 160062, Punjab, India
    J Pharm Sci 93:2177-83. 2004
    ....
  43. ncbi Transdermal delivery of tea catechins and theophylline enhanced by terpenes: a mechanistic study
    Jia You Fang
    Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Taoyuan, Taiwan
    Biol Pharm Bull 30:343-9. 2007
    ..The high enhancement by alpha-terpineol was due to macroscopic perturbation of the SC and the biological reaction in viable skin as evaluated by TEWL and colorimetry...
  44. ncbi Low-frequency ultrasound as a transcutaneous immunization adjuvant
    Ahmet Tezel
    Department of Chemical Engineering, University of California, Santa Barbara, CA 93106, USA
    Vaccine 23:3800-7. 2005
    ..These studies demonstrate generation of a potent systemic immune response through TCI without using toxin adjuvants or skin abrasion. Ultrasonic TCI offers a needle-free and painless mode of immunization...
  45. ncbi Skin penetration and distribution of polymeric nanoparticles
    R Alvarez-Román
    Centre interuniversitaire de recherche et d enseignement, Universities of Geneva and Lyon, Archamps, France
    J Control Release 99:53-62. 2004
    ..However, cross-sectional images revealed that these non-follicular structures did not offer an alternative penetration pathway for the polymer vectors, whose transport was clearly impeded by the stratum corneum...
  46. ncbi Formulation development of transdermal dosage forms: quantitative structure-activity relationship model for predicting activities of terpenes that enhance drug penetration through human skin
    L Kang
    Department of Pharmacy, National University of Singapore, Republic of Singapore
    J Control Release 120:211-9. 2007
    ..Possible mechanisms revealed by the QSAR model were discussed...
  47. ncbi Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study
    Clemente Muriel
    Pain Unit and Anaesthesiolog Department, Hospital Clinico de Salamanca, Salamanca, Spain
    Clin Ther 27:451-62. 2005
    ..8, 1.2, and 1.6 mg, respectively. Randomized, double-blind, placebo-controlled, Phase III clinical trials in >400 patients with severe pain of malignant or nonmalignant origin have shown the analgesic efficacy of buprenorphine TDS...
  48. ncbi Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study
    Jürgen Sorge
    Department of Anesthesiology, Surgical Intensive Care and Pain Therapy, Peine District Hospital, Virchowstrasse 8h, 31221 Peine, Germany
    Clin Ther 26:1808-20. 2004
    ..In 2001, the buprenorphine transdermal delivery system (TES) was introduced at 3 release rates (35, 52.5, and 70 microg/h) for the treatment of chronic cancer and noncancer pain...
  49. ncbi Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control
    Karel Pavelka
    Institute of Rheumatology, Prague, Czech Republic
    Curr Med Res Opin 20:1967-77. 2004
    ....
  50. ncbi Decision-making at the surface of the intact or barrier disrupted skin: potential applications for vaccination or therapy
    C D Partidos
    UPR 9021 CNRS, Institut de Biologie Moleculaire et Cellulaire, 15 rue Rene Descartes, 67084 Strasbourg, France
    Cell Mol Life Sci 62:1418-24. 2005
    ....
  51. ncbi Transdermal delivery of mixnoxidil with block copolymer nanoparticles
    Jongwon Shim
    Nanotechnology Research Laboratory, Skin Research Institute, R and D Center, AMOREPACIFIC Corp, 314 1 Bora ri, Giheug eup, Yeongin si, Gyeonggi Do, Seoul 449 729, South Korea
    J Control Release 97:477-84. 2004
    ..Confocal microscopy coupled with in vivo and in vitro skin permeation results demonstrated that nanoparticles containing solutes penetrated mainly via shunt routes like hair follicles, resulting in skin absorption of solutes...
  52. ncbi Assembled microneedle arrays enhance the transport of compounds varying over a large range of molecular weight across human dermatomed skin
    F J Verbaan
    Department of Drug Delivery Technology, Leiden Amsterdam Center for Drug Research, 2300 RA, Leiden, The Netherlands
    J Control Release 117:238-45. 2007
    ..However, some degradation was also observed for FITC-Dex and DCB. We conclude that assembled microneedle arrays can be used to deliver compounds through the skin up to a molecular weight of at least 72 kDa...
  53. ncbi Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials
    Rudolf Likar
    Pain Clinic, General Hospital Klagenfurt, Klagenfurt, Austria, and Pain Clinic, University of Erlangen Nurnberg, Germany
    Clin Ther 28:943-52. 2006
    ..Long-term data are essential to determining the performance of an analgesic in the management of chronic pain...
  54. ncbi Novel mechanisms and devices to enable successful transdermal drug delivery
    B W Barry
    Drug Delivery Group, School of Pharmacy, University of Bradford, Bradford BD7 1DP, UK
    Eur J Pharm Sci 14:101-14. 2001
    ..Of particular interest is the synergy between chemical enhancers, ultrasound, iontophoresis and electroporation...
  55. ncbi Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany
    Reinhard Sittl
    Pain Clinic, University of Erlangen, Erlangen, Germany
    Clin Ther 28:1144-54. 2006
    ..However, no information concerning the relationship between qualitative and quantitative dose changes is available...
  56. ncbi Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl
    S Grond
    Department of Anaesthesiology, University of Cologne, Germany
    Clin Pharmacokinet 38:59-89. 2000
    ..This would be beneficial for acute and/or breakthrough pain, and initial clinical trials are in progress...
  57. ncbi Buprenorphine in long-term control of chronic pain in cancer patients
    Maria Caterina Pace
    Department of Anesthesiology, Surgical and Emergency Sciences, Second University of Naples, Naples, Italy
    Front Biosci 12:1291-9. 2007
    ..01), mental health (P = 0.03) and vitality (P = 0.001). These data indicated that the BT group showed an improvement of pain and a positive effect on the quality life...
  58. ncbi Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol
    Susan Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
    Contraception 76:4-7. 2007
    ....
  59. ncbi Low-frequency sonophoresis: a review
    Samir Mitragotri
    Department of Chemical Engineering, University of California, Santa Barbara, CA 93106, USA
    Adv Drug Deliv Rev 56:589-601. 2004
    ..Mechanistic insights gained through a number of investigations are also reviewed. Finally, reports on the synergistic effect of low-frequency ultrasound with other enhancers including chemicals and iontophoresis are summarized...
  60. ncbi Current status and future potential of transdermal drug delivery
    Mark R Prausnitz
    School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
    Nat Rev Drug Discov 3:115-24. 2004
    ....
  61. ncbi The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy
    David F Archer
    Contraceptive Research and Development Program, Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA, USA
    Contraception 69:189-95. 2004
    ..Method compliance determines the proportion of perfect and imperfect dosing cycles, and together can form the basis for evaluating differences in efficacy based on differences in compliance...
  62. ncbi Rivastigmine exposure provided by a transdermal patch versus capsules
    Francois Mercier
    Novartis Pharma AG, Basel, Switzerland
    Curr Med Res Opin 23:3199-204. 2007
    ..The objective of this study was to evaluate the pharmacokinetics of rivastigmine following transdermal delivery by a patch versus oral delivery with conventional capsules in a population of AD patients...
  63. ncbi Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice
    Z Ding
    Department of Drug Delivery Technology, Leiden Amsterdam Centre for Drug Research, 2333 CC, Leiden, The Netherlands
    J Control Release 136:71-8. 2009
    ..These results indicate that TCI of DT and CT with microneedle treatment results in comparable protection as injection of DT-alum, and TCI of influenza vaccine adjuvanted with CT is superior to the injection of plain vaccine...
  64. ncbi A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen
    Arvind Vashisht
    Chelsea and Westminster Hospital, London, UK
    Gynecol Endocrinol 21:101-5. 2005
    ..There was no evidence of accumulation of progesterone with time, and further study is needed to assess the efficacy and safety of this combination of hormones...
  65. ncbi Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol
    Susan S Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
    Contraception 73:223-8. 2006
    ..There is concern that a new transdermal contraceptive patch containing ethinyl estradiol (EE) and the progestin norelgestromin increases the risk for venous thromboembolism (VTE) compared to previously marketed oral contraceptives (OCs)...
  66. ncbi Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study
    Fay Weisberg
    Department of Obstetrics and Gynaecology, University of Toronto, Toronto ON
    J Obstet Gynaecol Can 27:350-9. 2005
    ..To document Canadian women's experience with the transdermal contraceptive patch, a method delivering 150 microg norelgestromin and 20 microg ethinyl estradiol daily...
  67. ncbi Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans
    Annika Vogt
    Clinical Research Center for Hair and Skin Physiology, Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Chariteplatz 1, Berlin, Germany
    J Immunol 180:1482-9. 2008
    ..This study proposes new perspectives for the development of vaccination strategies that trigger T cell immune responses in humans...
  68. ncbi Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception
    Wolfgang Urdl
    Department for Obstetrics and Gynecology, Unit of Gynecological Endocrinology and Reproductive Medicine, University of Graz, Austria
    Eur J Obstet Gynecol Reprod Biol 121:202-10. 2005
    ..One thousand four hundred and eighty-nine women received a contraceptive patch (n = 846) or an OC (n = 643) for 6 or 13 cycles...
  69. ncbi Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application
    Gilbert Lefèvre
    Novartis Pharma AG, Exploratory Development, WSJ 210 4 25, CH 4002 Basel, Switzerland
    J Clin Pharmacol 47:471-8. 2007
    ..02). Pharmacokinetic profiles and adhesiveness of the upper back, chest, and upper arm, coupled with low rates of erythema at these sites, suggest their suitability for clinical use...
  70. ncbi Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients
    G Lefevre
    Novartis Pharma AG, Basel, Switzerland
    Clin Pharmacol Ther 83:106-14. 2008
    ..Average exposure with the 10 cm2 patch was comparable to the highest capsule dose (6 mg Q12H, i.e., 12 mg/day)...
  71. ncbi Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients
    Enno Freye
    Heinrich Heine University Clinics, Moorenstrasse, Dusseldorf, Germany
    Pain Pract 7:123-9. 2007
    ..Neither tolerance nor refractory effect following rotation from morphine to buprenorphine was noted. Conversion tables with a fixed conversion ratio are of limited value in patients treated with high-dose morphine...
  72. ncbi Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy
    Susan Richman
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University, New Haven, CT 06520, USA
    Menopause 13:148-55. 2006
    ..Additional studies are warranted to shed further light on the possible benefits of low-dose estrogen monotherapy for the prevention of bone loss in postmenopausal women...
  73. ncbi Transdermal buprenorphine in cancer pain and palliative care
    Reinhard Sittl
    Department of Anaesthesiology, Pain Therapy, University of Erlangen Nuremberg, Krankenhausstr 12, D 91054 Erlangen, Germany
    Palliat Med 20:s25-30. 2006
    ....
  74. pmc Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum
    Gregory M Glenn
    IOMAI Corporation, 20 Firstfield Road, Gaithersburg, MD 20878, USA
    Infect Immun 75:2163-70. 2007
    ....
  75. ncbi Transdermal hormonal contraception: benefits and risks
    Ronald T Burkman
    Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, MA 01199, USA
    Am J Obstet Gynecol 197:134.e1-6. 2007
    ..Despite this, the contraceptive patch may be an appropriate option for some patients...
  76. ncbi Transdermal delivery system of triamcinolone acetonide from a gel using phonophoresis
    Jae Heon Yang
    Department of Pharmacy, Woosuk University, Samrye 565 701, Korea
    Arch Pharm Res 29:412-7. 2006
    ..0, 3.0 MHz), intensity (1.0, 2.5 W/cm2), and duty cycle (continuous, pulse mode) using a 0.5% TA gel. The highest permeation was observed under the ultrasound treatment conditions of low frequency, high intensity, and in continuous mode...
  77. ncbi Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization
    Y L Zhao
    Cancer Biology Department, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Vaccine 24:1282-90. 2006
    ....
  78. ncbi Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine
    Jörg Filitz
    Department of Anesthesiology, University Hospital Erlangen, Krankenhausstrasse 12, D 91054 Erlangen, Germany
    Eur J Pain 10:743-8. 2006
    ..Furthermore, hemodialysis did not affect buprenorphine plasma levels, leading to stable analgesic effects during the therapy...
  79. ncbi Design of two liquid Ibuprofen-poloxamer-limonene or menthol preparations for dermal administration
    N Gonzalez
    Departamento de Farmacia, Facultad de Quimica, Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, Mexico
    Drug Deliv 14:287-93. 2007
    ..05). Results postulate that a liquid 30% poloxamer-based preparation of ibuprofen with d-limonene is possible and that it may be useful as a topical preparation of ibuprofen...
  80. ncbi Mass vaccination: solutions in the skin
    G M Glenn
    IOMAI Corporation, Gaithersburg, MD 20878, USA
    Curr Top Microbiol Immunol 304:247-68. 2006
    ..The combination of the skin immune system, safe use of potent adjuvants and ease of delivery suggests that skin delivery of vaccines can address multiple unmet needs for mass vaccination scenarios...
  81. ncbi Does the clinical use of ethanol-based hand sanitizer elevate blood alcohol levels? A prospective study
    Michael A Miller
    Department of Emergency Medicine, C R Darnall Army Medical Center, Hood, TX 76544, USA
    Am J Emerg Med 24:815-7. 2006
    ..To investigate the effect of frequent use of EBHS upon serum blood ethanol concentrations, we prospectively studied 5 volunteers undergoing frequent application of EBHS...
  82. ncbi Effect of DC/mDC iontophoresis and terpenes on transdermal permeation of methotrexate: in vitro study
    R Prasad
    Centre for Biomedical Engineering, Indian Institute of Technology, Hauz Khas, New Delhi 110016, India
    Int J Pharm 333:70-8. 2007
    ..Histopathological studies on treated skin samples, gave an insight about the anatomical changes brought by the application of various enhancers. Binary mixture of menthol and ethanol in combination with square wave gave best results...
  83. ncbi The mode of promoting activity of O-ethylmenthol as a transdermal absorption enhancer
    Yasuko Obata
    Department of Pharmaceutics, Hoshi University, Ebara 2 4 41, Shinagawa, Tokyo 142 8501, Japan
    Pharm Res 23:392-400. 2006
    ..The mode of action of O-ethylmenthol (MET), a promising compound to enhance transdermal drug delivery, was elucidated. Morphology of the skin treated with MET was investigated employing a laser scanning confocal microscopy...
  84. pmc Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice
    Sanjay Garg
    Influenza Division, Mail Stop G 16, CCID, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA
    Clin Vaccine Immunol 14:926-8. 2007
    ....
  85. ncbi Limonene GP1/PG organogel as a vehicle in transdermal delivery of haloperidol
    Perry Fung Chye Lim
    Department of Pharmacy, Faculty of Science, National University of Singapore, 18, Science Drive 4, Singapore 117543, Singapore
    Int J Pharm 311:157-64. 2006
    ..The rheology of the gel matrix influenced drug release rate in a manner described by several experimentally-derived correlations...
  86. pmc Coated microneedles for transdermal delivery
    Harvinder S Gill
    Wallace H Coulter Department of Biomedical Engineering at the Georgia Institute of Technology and Emory University, Atlanta, GA 30332 0100, USA
    J Control Release 117:227-37. 2007
    ..In conclusion, this study presents a simple, versatile, and controllable method to coat microneedles with proteins, DNA, viruses and microparticles for rapid delivery into the skin...
  87. ncbi Transcutaneous immunization with inactivated influenza virus induces protective immune responses
    Ioanna Skountzou
    Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, United States
    Vaccine 24:6110-9. 2006
    ..These results reveal a promising perspective for the application of transcutaneous immunization to prevent influenza epidemics as well as a range of other infectious diseases...
  88. ncbi The effect of terpene concentrations on the skin penetration of diclofenac sodium
    A Nokhodchi
    Medway School of Pharmacy, Central Ave, University of Kent and Greenwich, Chatham, Kent ME4 4TB, England, United Kingdom
    Int J Pharm 335:97-105. 2007
    ..The most outstanding penetration enhancer was nerolidol, providing an almost 198-fold increase in permeability coefficient of diclofenac sodium, followed by farnesol with a 78-fold increase...
  89. ncbi Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime
    Arvind Vashisht
    Chelsea and Westminster Hospital, London, UK
    BJOG 112:1402-6. 2005
    ..Many women are seeking alternatives to conventional forms of hormone replacement. This study evaluates the endometrial effects of natural progesterone cream used in conjunction with transdermal oestradiol...
  90. ncbi Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials
    Roger R Dmochowski
    Department of Urologic Surgery, Vanderbilt University, Nashville, TN 37235, USA
    World J Urol 23:263-70. 2005
    ..1% (3.3% discontinuation rate). Transdermal oxybutynin was shown to be efficacious, with a proven safety profile. It may be utilized for patients with overactive bladder as a treatment option that could enhance compliance...
  91. ncbi Coating formulations for microneedles
    Harvinder S Gill
    Wallace H Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Georgia Institute of Technology, Atlanta, GA 30332 0535, USA
    Pharm Res 24:1369-80. 2007
    ....
  92. ncbi Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial
    Bruce Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    Obstet Gynecol 104:443-51. 2004
    ....
  93. pmc Effect of the ethinylestradiol/norelgestromin contraceptive patch on body composition. Results of bioelectrical impedance analysis in a population of Italian women
    Antonio Piccoli
    Department of Medical and Surgical Sciences, University of Padova, Italy
    Nutr J 7:21. 2008
    ....
  94. ncbi Fluorescein permeability and electrical resistance of human skin during low frequency ultrasound application
    Limary M Cancel
    Biomolecular Transport Dynamics Laboratory, Department of Chemical Engineering, The Pennsylvania State University, University Park, PA 16802, USA
    J Pharm Pharmacol 56:1109-18. 2004
    ..In addition, a quantitative analysis of the thermal and convective dispersion effects associated with ultrasound application showed that each contributes significantly to the overall permeability enhancement observed...
  95. ncbi Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease
    Peter A LeWitt
    Department of Neurology, Wayne State University School of Medicine, and Henry Ford Hospital Franklin Pointe Medical Center, 26400 West 12 Mile Road, Southfield, MI 48034, USA
    Clin Neuropharmacol 30:256-65. 2007
    ....
  96. ncbi Pretreatment with transdermal nicotine enhances some of ethanol's acute effects in men
    Elena M Kouri
    Behavioral Psychopharmacology Research Laboratory, McLean Hospital Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Drug Alcohol Depend 75:55-65. 2004
    ..These findings suggest that nicotine enhances some of the positive subjective effects of acute ethanol and may help explain the high prevalence of the combined use of these two drugs...
  97. ncbi Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch
    Gregory M Glenn
    IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA
    Expert Rev Vaccines 6:809-19. 2007
    ..In this review, we integrate these concepts, update the clinical data and look to the future...
  98. ncbi Clinical, biometric and structural evaluation of the long-term effects of a topical treatment with ascorbic acid and madecassoside in photoaged human skin
    Marek Haftek
    Universite Lyon 1, EA4169 Laboratory for Dermatological Research, Edouard Herriot Hospital, Lyon, France
    Exp Dermatol 17:946-52. 2008
    ..Two-thirds of the subjects showed an improvement. The re-appearance of a normally structured elastic fibre network was observed. Our results revealed a functional and structural remodelling of chronically sun-damaged skin...
  99. ncbi Persistent retention of acetic acid is associated with complete tumour necrosis in patients with hepatocellular carcinoma undergoing percutaneous acetic acid injection
    T I Huo
    Division of Gastroenterology, Dept of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    Scand J Gastroenterol 39:168-73. 2004
    ..This study aimed to determine the occurrence and predictive value of persistent intra-tumoral retention of acetic acid after PAIT...
  100. ncbi Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch
    David M Frerichs
    IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA
    Vaccine 26:2782-7. 2008
    ..The development of a simple, single-use, disposable device that is well-tolerated and allows disruption to be modulated represents an important step forward in physical penetration enhancement for the skin...
  101. pmc Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine
    Paul Stickings
    Division of Bacteriology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
    Infect Immun 76:1766-73. 2008
    ..These findings highlight the promising prospect of using booster administrations of CRM(197) via the transcutaneous route to establish good herd immunity against diphtheria...

Research Grants67

  1. Therapeutic vaccination against genital HPV infection
    Yung Nien Chang; Fiscal Year: 2013
    ..TA-HPV is vaccinia virus engineered to express the E6 and E7 genes from HPV16 and HPV18. Cutaneous administration of TA-HPV to nearly a hundred patients with HPV16+ cervical cancer and anogenital neoplasias failed to ..
  2. Mucosal Immune-enhancing Delivery System for HIV vaccines
    MICHAEL SEJR VAJDY; Fiscal Year: 2010
    ..This project pertains to designing a novel, safe and effective Mucosal Immune-enhancing Delivery System for HIV vaccine development that can protect the public against new infections with the HIV virus. ..
  3. Comparative In Vivo Biodistribution of Characterized Manufactured Nanomaterials
    Nancy A Monteiro Riviere; Fiscal Year: 2010
    ..These coordinated studies will provide data to link physical chemical characterizations to in vivo MNM disposition. ..
  4. Novel therapeutics for learning and memory disorders
    Joseph Moskal; Fiscal Year: 2006
    ..We will also compare the bioavailability of GLYX-13 by intravenous, oral, and sub-cutaneous administration. Additionally, we will evaluate availability to the CNS via monitoring GLYX-13 effects on basal and ..
  5. Non-viral Cutaneous Gene Delivery
    Mohammed Kashani Sabet; Fiscal Year: 2005
    ..this need by focusing on increasing both the level and the duration of expression of genes delivered by cutaneous administration of plasmid DNA, using recent advances in gene transfer techniques...
  6. A NEW METHOD FOR TREATING SLEEP DISORDERS
    Larry Nichols; Fiscal Year: 2000
    ..This method utilizes a new transdermal formulation discovered by Biotek that delivers melatonin through the skin much faster than previously investigated media, a delivery both non-oral and non-invasive. ..
  7. TOPICAL APPLICATION OF STATINS FOR OSTEOPOROSIS
    I Garrett; Fiscal Year: 2000
    ..Our data suggests this route of delivery may lead to enhanced pharmacologic effects of the statin on bone. ..
  8. VACCINATION BY TOPICAL APPLICATION OF CONDENSED DNA
    Mark Cooper; Fiscal Year: 2000
    ..Specific immunity to DNA-encoded antigens has been observed, although the immune response following cutaneous administration has been less robust than either IM vaccination protocols or recombinant protein vaccines...
  9. A Transdermal Hypolipidemic Niacin Prodrug
    Hyuntae Kim; Fiscal Year: 2002
    ..We also will compare the effects of oral and transdermal administration of their ability to favorably alter lipid profiles in a double transgenic mouse model that contains lipoprotein profiles similar to the human. ..
  10. Neurocognition, Nicotine and Polysubstance Abuse
    Sara Nixon; Fiscal Year: 2006
    ..To facilitate this secondary aim, we have instituted plans to over-sample American Indians (Al), African American (AA) and female participants. ..
  11. SEX DIFFERENCES IN NICOTINE REINFORCEMENT: HUMAN/ANIMAL
    Kenneth Perkins; Fiscal Year: 2003
    ....
  12. Affect, Context, and Placebo Responses to Nicotine
    Kenneth Perkins; Fiscal Year: 2005
    ..Secondary analyses may identify important individual characteristics associated with placebo responses, aiding in the prediction of which smokers ultimately are likely to benefit most from manipulation of placebo effects. ..
  13. INDIVIDUAL VARIATION IN NICOTINE SENSITIVITY IN HUMANS
    Kenneth Perkins; Fiscal Year: 2003
    ..e., in nicotine-naive individuals). Results will provide directions for future research on vulnerability to tobacco dependence and for targeted efforts to prevent smoking onset. ..
  14. DISCRIMINATIVE STIMULUS EFFECTS OF NICOTINE
    Kenneth Perkins; Fiscal Year: 2001
    ....
  15. Tobacco Smoking, Nicotine and Negative Affect Relief
    Kenneth Perkins; Fiscal Year: 2009
    ..In sum, this research will help address the fundamental question of why cigarette smoking is reinforcing. ..
  16. Pharmacogenetic Investigation of Naltrexone
    Caryn Lerman; Fiscal Year: 2007
    ..The long-term objective of this research is to discover and develop new pharmacogenetic treatment models that can be readily translated to the clinical setting to individualize pharmacotherapy and maximize effectiveness. ..
  17. Interventions for Tobacco Dependent Adolescents
    Dorothy Hatsukami; Fiscal Year: 2005
    ....
  18. Formulated Patch for Topical Influenza Vaccine
    Gregory Glenn; Fiscal Year: 2004
    ..Needle-free may also aid in the extension of use of a flu patch into the pediatric population where influenza immunization is now recommended by the ACIP and will be a subsequent goal of this development program. ..
  19. Innovative Interventions for Smoking Cessation
    Dorothy K Hatsukami; Fiscal Year: 2010
    ..The results of this study will provide useful information on directions to pursue to improve our pharmacotherapies and behavioral treatments and to better understand the various aspects of addiction. ..
  20. SCALING THE REINFORCING VALUE OF CIGARETTE SMOKE
    Jed Rose; Fiscal Year: 2003
    ..The results will lead to a better understanding of the role of pharmacologic and sensory/behavioral cues in nicotine addiction and smoking cessation. ..
  21. Transcutaneous Immunization for an Anthrax Vaccine
    Gregory Glenn; Fiscal Year: 2005
    ....
  22. BIOBEHAVIORAL LUNG CANCER PREVENTION PROGRAM
    Caryn Lerman; Fiscal Year: 2004
    ..The long-term objective is to provide information necessary to match smoking cessation treatments to individuals, based on their genetic predispositions. ..
  23. TREATMENT OF SMOKELESS TOBACCO USERS
    Dorothy Hatsukami; Fiscal Year: 2008
    ..PERFORMANCE SITE ========================================Section End=========================================== ..
  24. Smoking Cessation for Head and Neck Cancer Patients
    Robert Schnoll; Fiscal Year: 2006
    ..In turn, our findings may help guide the implementation of smoking cessation treatments for all cancer patients within Comprehensive Cancer Centers in the US. ..
  25. TRANSCUTANEOUS IMMUNIZATION FOR TETANUS BOOSTER
    Gregory Glenn; Fiscal Year: 2003
    ..Additionally, the Transcutaneous booster will decrease the risk of needle-sticks and related disease, and reduce personnel and equipment requirements related to tetanus immunization. ..
  26. TOBACCO EXPOSURE REDUCTION
    Dorothy Hatsukami; Fiscal Year: 2008
    ..The results of research from this TTURC will provide the scientific basis for urgent policy, public education, and regulatory efforts to reduce tobacco harm. ..
  27. Mechanisms Linking Hostility and Smoking
    Christopher Kahler; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  28. Electroporation and transcutaneous extraction of drugs
    SATHYANARAYANA MURTHY; Fiscal Year: 2006
    ..Further we also plan to correlate the time course of unbound ciprofloxacin in dermal ECF with that in synovial fluid determined by microdialysis in rat. [unreadable] [unreadable] [unreadable]..
  29. Validating Novel Familial Phenotypes of Drug Abuse
    Stephen Faraone; Fiscal Year: 2007
    ..State of the art statistical techniques will be employed. ..
  30. International Multi-Center ADHD Genetics Project
    Stephen Faraone; Fiscal Year: 2007
    ..abstract_text> ..
  31. Juvenile Bipolar Disorder and Substance Abuse
    Timothy E Wilens; Fiscal Year: 2010
    ..Since BPD is identifiable and treatable, findings from the four-year follow-up will provide valuable information to formulate prevention and early intervention strategies. ..
  32. Searching for ADHD Susceptibility Genes
    Stephen V Faraone; Fiscal Year: 2010
    ..That, in turn, should facilitate the search for newer, more effective treatments for the disorder. ..
  33. Evaluating Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
    Jon Ebbert; Fiscal Year: 2009
    ..No drug therapies have been shown to be effective for helping smokeless tobacco users quit for good. The purpose of this study is to test drugs that can be used to help smokeless tobacco users quit for good. ..
  34. 2/5-The Psychiatric GWAS Consortium: Integrated & Coordinated GWAS Meta-Analyses
    Stephen Faraone; Fiscal Year: 2008
    ..Finally, the PGC proposes to abide as fully as possible with the NIH's GWAS data sharing policies and we provide a detailed data sharing plan and timetable. [unreadable] [unreadable] [unreadable]..
  35. Neuroimaging Attentional Impairment During Abstinence
    Francis McClernon; Fiscal Year: 2008
    ..Dr. McClernon will continue to administer current awards and compete for additional extramural funding while he completes the goals of the application. [unreadable] [unreadable] [unreadable] [unreadable]..
  36. Analysis of an ADHD Whole Genome Association Scan
    Stephen Faraone; Fiscal Year: 2007
    ..All genotype data generated by the GAIN whole genome association scan will be made available to the scientific community by GAIN as soon as the genotypes are completed. [unreadable] [unreadable] [unreadable]..
  37. Psychobiological /Genetic Determinants-Smoking Cessation
    Sean David; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  38. AN ECOGENETIC STUDY OF ADHD
    Stephen Faraone; Fiscal Year: 2003
    ..Furthermore, no studies have used an ecogenetic approach to sharpen the accuracy of risk prediction. ..
  39. Primary Care Genetics Cancer Prevention Conference
    Sean David; Fiscal Year: 2003
    ..abstract_text> ..
  40. PEDIATRIC BIPOLAR COLLABORATIVE MOOD STABILZER TRAIL
    Robert Findling; Fiscal Year: 2003
    ..Lastly, this trial will provide descriptive information on the stability of acute phase response to monotherapy over a 16 week continuation phase. ..
  41. High Dose Nicotine Patch Therapy for Spit Tobacco Users
    Jon Ebbert; Fiscal Year: 2004
    ..Our goal is to reduce the prevalence of ST use and decrease the incidence of oropharyngeal cancer through the development of effective treatment options for ST users. ..
  42. Drug Cue Reactivity in Smokers: An fMRI Investigation
    Francis McClernon; Fiscal Year: 2002
    ..The results of this study will enhance our understanding of the neurobiological basis of tobacco dependence, inform treatment development, and generate additional hypotheses and research plans. ..
  43. TESTING THE VALIDITY OF ADULT ATTENTION DEFICIT DISORDER
    Stephen Faraone; Fiscal Year: 2002
    ..Thus, if founded, we expect that the proposed work will lead to a program of research that can both clarify the nosological complexities of adult ADHD and clarify the nature of genes that are risk factors for the disorder. ..
  44. LC-MS/MS Methods for Analysis of Hemoglogbin Adducts
    Timothy Fennell; Fiscal Year: 2004
    ..abstract_text> ..
  45. Improving Smoking Cessation Outcomes in Heavy Drinkers
    Christopher Kahler; Fiscal Year: 2006
    ..Developing effective interventions that address alcohol use during smoking cessation treatment can make a major public health impact on this large, yet neglected, subgroup of smokers. ..
  46. MIDCAREER INVESTIGATOR AWARD IN NEURO-AIDS RESEARCH
    David Simpson; Fiscal Year: 2005
    ..The Neuro-Adherence Program will assess the affect of neurological disease on patients' adherence to medical regimens, and the impact of education and support groups on adherence. ..
  47. Brief Dental Office Intervention with Tobacco Quitline
    Jon Ebbert; Fiscal Year: 2005
    ..S. adult population smoking; and 3) 75% of smokers quitting for at least one day or longer because they are trying to quit. ..
  48. Substance Abuse in ADHD Girls
    Timothy Wilens; Fiscal Year: 2006
    ..Thus, the research, approach, and goals of this R01 application are consistent with those underscored in the PA and by the Institute of Medicine as being of the highest research priority. ..
  49. LONG TERM DRUG ABUSE IN ADHD
    Timothy Wilens; Fiscal Year: 2002
    ..abstract_text> ..
  50. Androgen deficiency and Osteopenia in Anorexia Nervosa
    Karen Miller; Fiscal Year: 2002
    ..In the third phase of the study, we will examine the effects of administering testosterone on bone density and body mass. ..
  51. ESTROGEN COMPOUNDS, COGNITION & DEMENTIA IN OLDER WOMEN
    Kristine Yaffe; Fiscal Year: 2002
    ..This award will foster the applicant's development towards becoming an independent investigator in aging research. ..
  52. Ethnic Health/Motivating HIV+ Latinos to Quit Smoking
    Cassandra Stanton; Fiscal Year: 2009
    ..abstract_text> ..
  53. AEROSOL BASED NANOPARTICAL DRUG DELIVERY SYSTEM--TB
    Lawrence Ng; Fiscal Year: 2002
    ..It is expected this multidisciplinary approach will provide significant advances in the treatment of TB and other airway diseases in which sustained drug release or targeting AMs would be advantageous. ..
  54. IMMUNODERMATOLOGICAL THERAPY OF SKIN CANCER
    Craig Elmets; Fiscal Year: 2003
    ..The ultimate goal of this proposal is to generate new knowledge that can be used to develop new and better strategies for the control of non-melanoma and melanoma skin cancer. ..
  55. MICROFABRICATED MICRONEEDLES FOR DRUG DELIVERY
    MARK PRAUSNITZ; Fiscal Year: 2001
    ..g., proteins, DNA) over hours to days. ..
  56. MECHANISMS OF CUTANEOUS ACTIVE VASODILATION
    Dean Kellogg; Fiscal Year: 2008
    ..In addition, intradermal microdialysis will be combined with measurements of bioavailable NO by NO-selective amperometric electrode to define further how the NO system functions in cutaneous active vasodilation. ..
  57. RESPONSE VARIABILITY IN STIMULANT TREATMENT OF ADHD
    James McGough; Fiscal Year: 2004
    ..In addition to funding the candidate's transition to independent research the proposed study would also contribute to our knowledge of the basis of individual response to medication in psychiatric disorders. ..
  58. Pharmacologically Enhanced Fracture Repair by Statins
    Gloria Gutierrez; Fiscal Year: 2004
    ..abstract_text> ..
  59. Novel Active Repressor Model of Human LDL-Receptor Regulation
    Johannes Veldhuis; Fiscal Year: 2008
    ..This would represent a new treatment approach for patients with atherosclerotic disease. [unreadable] [unreadable] [unreadable] [unreadable]..
  60. ENSEMBLE MODEL OF STRESS ACTH-ADRENAL AXIS
    Johannes Veldhuis; Fiscal Year: 2005
    ....
  61. Mechanisms of Ultrasound-Mediated Bioeffects
    MARK PRAUSNITZ; Fiscal Year: 2006
    ..During the final year, mechanistic findings will be used to design and test ultrasound protocols that optimize molecular uptake and cell viability. ..
  62. Health Promotion Intervention:Sedentary Care Patients
    Kerry Kuehl; Fiscal Year: 2008
    ..Outcomes will be assessed using repeated measures design. Relationships among mediators, the intervention, and the outcome measures will be identified. ..
  63. RUPP-PI
    Oscar Bukstein; Fiscal Year: 2006
    ..The expertise and experience at this RUPP-PI site also will be directed to train new investigators. In creating TASA, a collaborative group of 8 applicants forged the ability to work together. ..
  64. Elucidating the Neurobiology of Postpartum Depression
    Eydie Moses Kolko; Fiscal Year: 2006
    ..abstract_text> ..